INDOCO REMEDIES LIMITED



Regd. Office: Indoco House, 166, CST Road, Santacruz (East), Mumbai 400 098

Tel:+91-22-26541851/55 Fax:+91-22-26520787 Email compliance.officer@indoco.com

Web:www.indoco.com CIN:L85190MH1947PLC005913

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2014

PART- I (₹ In Lacs)

<u> </u>	11-1 	0	0	0	Aller a conseque	NI'	(K III Lacs)
Sr. No		Quarter ended 31.12.2014 (Unaudited)	Quarter ended 30.09.2014 (Unaudited)	Quarter ended 31.12.2013 (Unaudited)	Nine month ended 31.12.2014 (Unaudited)	Nine month ended 31.12.2013 (Unaudited)	Year ended 31.03.2014 (Audited)
1	Income from Operations						
	(a) Gross Sales / Income from Operations	21,544	22,955	19,171	64,623	54,126	73,011
	(b) Excise Duty	(251)	(313)	(330)	(892)	(975)	(1,274)
	(c) Net Sales / Income from Operations (a-b)	21,293	22,642	18,841	63,731	53,151	71,737
			,-		55,151		,
	(d) Other Operating Income	373	201	(60)	642	1,258	1,034
	Total Income from Operations (Net) (c+d)	21,666	22,843	18,781	64,373	54,409	72,771
2	Expenses						
	(a) Cost of materials consumed	6,409	7,421	5,226	20,116	16,830	23,016
	(b) Purchases of stock-in-trade	1,252	1,574	905	3,974	3,195	4,005
	(c) Changes in inventories of finished goods,	107	(1,024)	1,109	(1,094)	760	(105)
	work-in-progress and stock-in-trade						
	(d) Employee Benefits expense	3,471	3,596	3,223	10,440	9,445	12,905
	(e) Depreciation and Amortisation expense	1,198	1,315	802	3,460	2,307	3,091
	(f) Research & Development Expense	503	489	367	1,422	1,025	1,443
	(g) Other Expenses	5,655	5,924	4,966	16,725	14,433	19,500
	Total Expenses	18,595	19,295	16,598	55,043	47,995	63,855
3	Profit from Operations before Other Income,	3,071	3,548	2,183	9,330	6,414	8,916
١,	finance costs and Exceptional Items (1-2)	00	50	4.4	107	70	475
	Other Income	20	56	11	137	73	175
5	Profit from ordinary activities before finance	3,091	3,604	2,194	9,467	6,487	9,091
6	costs and Exceptional Items (3+4) Finance Costs	271	268	386	813	1,535	1,880
_	Profit from ordinary activities after finance cost	2,820	3,336	1,808	8,654	4,952	
'	but before Exceptional Items (5-6)	2,020	3,330	1,000	0,034	4,952	7,211
8	Exceptional Items			_			_
	Profit from Ordinary activities before tax (7-8)	2,820	3,336	1,808	8,654	4,952	7,211
	Tax Expenses	658	1,095	396	2,248	1,018	1,421
	Net Profit from Ordinary activities after tax (9-10)	2,162	2,241	1,412	6,406	3,934	5,790
	Extraordinary Items		-,	-,	-	-	-
	Net Profit for the period (11-12)	2,162	2,241	1,412	6,406	3,934	5,790
	Paid up Equity Share Capital (Face value ₹2/-each)	1,843	1,843	1,843	1,843	1,843	1,843
	Reserves excluding Revaluation Reserves as per	1,515	1,515	1,010	1,010	1,010	43,854
	Balance Sheet of Previous accounting year						
16	Earnings per share (before and after						
	extraordinary items)						
	(of ₹ 2/- each) (not annualised):						
	(a) Basic	2.35	2.43	1.53	6.95	4.27	6.28
	(b) Diluted	2.35	2.43	1.53	6.95	4.27	6.28

PART- II Select Information for the Quarter and nine months ended 31st December, 2014								
Sr. No	Particulars	Quarter ended 31.12.2014 (Unaudited)	Quarter ended 30.09.2014 (Unaudited)	Quarter ended 31.12.2013 (Unaudited)	Nine month ended 31.12.2014 (Unaudited)	Nine month ended 31.12.2013 (Unaudited)	Year ended 31.03.2014 (Audited)	
Α	PARTICULARS OF SHAREHOLDING							
1	Public shareholding							
	- Number of Shares	375,51,521	375,52,721	375,78,444	375,51,521	375,78,444	376,01,399	
	- Percentage of Shareholding	40.75	40.75	40.78	40.75	40.78	40.80	
2	Promoters and promoter group shareholding							
	a) Pledged/Encumbered							
	- Number of shares	-	-	-	-	-	-	
	- Percentage of shares (as a % of the total	-	-	-	-	-	-	
	shareholding of promoter and promoter group)							
	- Percentage of shares (as a % of the total share	-	-	-	-	-	-	
	capital of the company)							
	b) Non-encumbered							
	- Number of shares	545,98,834	545,97,634	545,71,911	545,98,834		545,48,956	
	- Percentage of shares (as a % of the total	100.00	100.00	100.00	100.00	100.00	100.00	
	shareholding of promoter and promoter group)							
	- Percentage of shares (as a % of the total share	59.25	59.25	59.22	59.25	59.22	59.20	
	capital of the company)							
Sr. No	Particulars		3 months ended 31.12.2014					
В	INVESTOR COMPLAINTS					•		
	Pending at the beginning of the quarter		Nil					
	Received during the quarter		4					
	Disposed of during the quarter		4				l	
	Remaining unresolved at the end of the quarter		Nil					

Notes:

 $1\quad \hbox{The company has only one primary reportable segment of activity, namely, Pharmaceuticals}.$

$\underline{\text{Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:} \\$

(₹ In Lacs)

Net Sales and Income from Operations	Quarter	Quarter	Quarter	Nine month	Nine month	Year ended
	ended	ended	ended	ended	ended	31.03.2014
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	(Audited)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
India	12,965	14,469	12,067	40,235	35,227	46,302
Outside India	8,328	8,173	6,774	23,496	17,924	25,435
Total	21,293	22,642	18,841	63,731	53,151	71,737

- 2 The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 30th January, 2015.
- 3 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 31st December, 2014.
- 4 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

By Order of the Board For Indoco Remedies Ltd

Place : MumbaiSuresh G. KareDate : 30th January, 2015Chairman